AIM ImmunoTech (AIM) announces NYSE delisting, plans to appeal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
April 4, 2025 4:45 PM EDTOCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM or the Company) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the NYSE American or the Exchange) that it had suspended trading of the Companys common stock and of its determination to commence delisting proceedings of the Companys common stock from the Exchange pursuant to Section 1003(f)(v) of the... More
